Navigation Links
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
Date:6/2/2008

ave been treated with the second schedule, confirming the excellent safety profile of the drug. The dose escalation is still ongoing.

"Our recent data suggest, that intravenous infusion of AP 12009 is safe in patients suffering from malignant tumors, such as pancreatic carcinoma or melanoma. The survival data, observed in this Phase I/II study are very good, given the poor prognosis associated with these diseases," said Dr. Hubert Heinrichs, Chief Medical Officer of Antisense Pharma.

To further study the potential of the antisense treatment in pancreatic carcinoma, a Phase II study on AP 12009 in combination with the standard of care is scheduled to start in 2009. A Phase II study in malignant melanoma in combination with the current standard of treatment is currently being planned.

"The results of the Phase I/II study underscore again the high efficacy of AP 12009, which we have seen in high-grade glioma patients in the active-controlled Phase IIb study AP12009-G004. This study showed a strong survival benefit in patients treated with AP 12009 compared to standard chemotherapy treatment," commented Dr. Karl-Hermann Schlingensiepen, CEO of Antisense Pharma. "We have made huge progress in bringing the drug AP 12009 to patients with highly malignant tumors, who are in need of better therapies that prolong survival benefited by high quality of life."

Literature

(1) Hilbig, A. et al. "Systemic i.v. Administration of AP 12009: Preliminary Results of a Phase I/II Study in Pancreatic Carcinoma, Malignant Melanoma, or Colorectal Carcinoma", ASCO Annual Meeting, 2008, Abstract ID 4621

The Phase I/II study AP 12009-P001

In the open-label, multicenter, dose-escalation Phase I/II study, patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) repeatedly receive intravenous infusions of AP 12009. Primary study objective is to determine the maximu
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
2. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
3. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
7. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
8. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
9. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
10. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
11. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Trial to Examine Safety and Efficacy of DARA ... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced the initiation of a Phase 2b,clinical ... candidate.,This randomized, double-blind, placebo and active-controlled,parallel-group study is ...
... 29 A study reported in,the journal ... the,Ciliary Neurotrophic Factor gene (CNTF) may affect ... Vanda Pharmaceuticals,Inc., included patients with acute symptoms ... (iloperidone), a novel atypical,antipsychotic agent currently under ...
Cached Medicine Technology:Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 4Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... discovery by Northwestern Medicine scientists could lead to potential ... in people with scleroderma. , Fibrosis, or scarring, ... of the skin and lungs can lead to serious ... concept for new therapeutic options centers on findings made ... who identified the role that a specific protein plays ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... Featured March 7-12 in San Diego FAIRFAX, ... Radiology (SIR) will present the latest research on ... cancer; herniated disks; peripheral arterial disease (PAD) and ... 34th Annual Scientific Meeting, March 7-12 at the ...
... Feb. 25 Mark Leventhal, Esq., the Founder and ... in the nation executive weight loss consulting service for ... County (OH) Bar Association at 11:45 am today at ... Leventhal Consulting takes a one-on-one personalized approach, and works ...
... Deborah Way, MD, of The Visiting Nurse Association of ... in hospice and palliative medicine from the American Board ... medical director of VNA,s Hospice of Philadelphia which provides ... in the Greater Philadelphia region.ABIM works to enhance the ...
... the country to confront the challenge of eating disordersNational Eating ... a note from my mom on the kitchen table when ... you have bulimia. We need to talk.," (EXCERPT ... the right way to discuss an eating disorder with a ...
... much of the state of California during mid- to ... many regions of the State. A study conducted by ... Natural Resources Defense Council, and the California Department of ... had a substantial impact on morbidity throughout California, resulting ...
... VEGAS, Feb. 25 From children to ... life every day. The focus of the American ... Advertising Campaign is on preventing and healing joint pain, ... athletes, knees. The AAOS is committed to helping ...
Cached Medicine News:Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 3Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 4Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 5Health News:Mark Leventhal to Address the Lake County (OH) Bar Association 2Health News:Hospice of Philadelphia Medical Director, Deborah Way, MD, Earns Certification from the American Board of Internal Medicine 2Health News:The Renfrew Center Foundation Partners with 2008 Miss America Kirsten Haglund and Her Mom, Iora Haglund, to Empower Parents to Fight Eating Disorders 2Health News:The Renfrew Center Foundation Partners with 2008 Miss America Kirsten Haglund and Her Mom, Iora Haglund, to Empower Parents to Fight Eating Disorders 3Health News:Study analyzes 2006 California heat wave's substantial effect on morbidity 2Health News:Study analyzes 2006 California heat wave's substantial effect on morbidity 3Health News:The Most Breaking News in the Joint 2Health News:The Most Breaking News in the Joint 3Health News:The Most Breaking News in the Joint 4
... Soft, foam-lined FoamWrap ThumWrap Splints offer support ... Ideal to relieve mild pain or strain ... activities. Choose either the rigid or the ... amount of support. Washable and breathable, the ...
... lightweight orthosis is designed to comfortably restrict ... holding the hand in a neutral position. ... grade thermoplastic whose unique characteristics offer durable ... provides rigid cast-like immobilization of the wrist, ...
... is a custom wrist orthotic designed to limit the ... patient's maximum range-of-motion. , ,Indications: , Wrist ... fibrocartilage complex , Coles fracture - distal ... Partial tendon rupture , ORIF - Open ...
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
Medicine Products: